½ÃÀ庸°í¼­
»óǰÄÚµå
1604760

ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå : ¿öÅ©Ç÷οì, À¯Çü, ±Ô¸ðº° ¿¹Ãø(2025-2030³â)

Automated & Closed Cell Therapy Processing Systems Market by Workflow (Apheresis, Cryopreservation, Expansion), Type (Non-Stem Cell Therapy, Stem Cell Therapy), Scale - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 197 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀº 2023³â¿¡ 9¾ï 4,394¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 10¾ï 8,797¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 15.74%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 26¾ï 2,676¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛÀº Áٱ⠼¼Æ÷ Ä¡·á³ª À¯ÀüÀÚ Ä¡·á µîÀÇ Ä¡·á¹ýÀÇ Á¦Á¶¿Í ½ºÄÉÀϸµ¿¡ ÃÊÁ¡À» ¸ÂÃá Çö´ëÀÇ Àç»ý ÀÇ·á¿¡ ÇʼöÀûÀÎ ÄÄÆ÷³ÍÆ®ÀÔ´Ï´Ù. Á¦Á¶ °øÁ¤À» °¡´ÉÇÏ°Ô ÇÏ°í ¼¼Æ÷ Ä¡·á Á¦Ç°ÀÇ Àϰü¼º°ú ±ÔÁ¦ Áؼö¸¦ º¸ÀåÇÕ´Ï´Ù. È®Àå °¡´ÉÇϰí È¿À²ÀûÀÌ¸ç ºñ¿ë È¿À²ÀûÀÎ »ý»ê ¼Ö·ç¼ÇÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. Áٱ⠼¼Æ÷ ¹× Àç»ý ÀÇÇп¡ »ç¿ëµÇ´Â ´Ù¸¥ ¼¼Æ÷ Á¦Ç°ÀÇ »ý»ê¿¡ ¸Å¿ì Áß¿äÇÏ¸ç ¾Ï, À¯Àü¼º Áúȯ ¹× ÅðÇ༺ ÁúȯÀÇ Ä¡·á¿¡ ±Ã±ØÀûÀÎ ÀÌÁ¡À» Á¦°øÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 9¾ï 4,394¸¸ ´Þ·¯
ÃßÁ¤³â(2024) 10¾ï 8,797¸¸ ´Þ·¯
¿¹Ãø³â(2030) 26¾ï 2,676¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 15.74%

½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ¼¼Æ÷ Ä¡·á ±â¼úÀÇ Áøº¸, ¿¬±¸ ÀÚ±Ý Áõ°¡, Àç»ý ÀÇ·á¿¡ ´ëÇÑ Àνİú µµÀÔ Áõ°¡ÀÔ´Ï´Ù. ±â¾÷°ú ¿¬±¸±â°üÀÇ Àü·«Àû Á¦ÈÞ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. Çâ»ó½Ã۱â À§ÇØ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» ÃÖÀûÈ­ÇÏ°í ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú AI ÁÖµµ ǰÁú °ü¸®¸¦ Á¦°øÇÏ´Â ÅëÇÕ Ç÷§ÆûÀ» °³¹ßÇÏ´Â µ¥ ÀÖ½À´Ï´Ù. »ç¿ëÀÚ ÀÎÅÍÆäÀ̽ºÀÇ ´Ü¼øÈ­, ±ÔÁ¦ ÁؼöÀÇ Ã¶ÀúÇÏ°Ô ÁÖ·ÂÇØ¾ßÇÕ´Ï´Ù.

½Ã½ºÅÛ µµÀÔÀÇ °íºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ »óȲ, ±â¼úÀû º¹À⼺ µîÀÇ °úÁ¦´Â ¼ºÀåÀ» ÀúÇØÇÒ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. Çʿ伺µµ Àå¾Ö¹°ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ±Øº¹Çϱâ À§ÇØ ±â¾÷Àº ±³À° ÇÁ·Î±×·¥¿¡ ÅõÀÚÇϰí Çõ½ÅÀ» À§ÇØ Çмú±â°ü°ú Çù·ÂÇØ¾ß ÇÕ´Ï´Ù. ÀÌ ºÐ¾ß¿¡´Â ¸ðµâÇü ½Ã½ºÅÛ ¼³°èÀÇ Áøº¸, Ä¡·á¿ëÀÇ »õ·Î¿î ¼¼Æ÷ À¯ÇüÀÇ Å½±¸, ÇÁ·Î¼¼½º Á¦¾î °­È­¸¦ À§ÇÑ IoT ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù. Ư¡À̱⠶§¹®¿¡ ¼¼°èÀûÀ¸·Î ±ÞÁõÇÏ´Â ¼¼Æ÷ Ä¡·á ¼ö¿ä¸¦ È¿À²ÀûÀ¸·Î Ȱ¿ëÇϱâ À§Çؼ­´Â Áö¼ÓÀûÀÎ Çõ½Å°ú Àü·«Àû Æ÷Áö¼Å´×ÀÌ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ : ±Þ¼ÓÈ÷ ÁøÈ­ÇÏ´Â ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³

ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. Àû ÀÇ»ç °áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæ ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦ÀûÀÎ ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ½°ú µ¿½Ã¿¡ ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • Àç»ý ÀÇ·á ¹× ¼¼Æ÷ Ä¡·áÀÇ ÀαⰡ ³ô¾Æ
    • ºñ¿ëÈ¿°ú°¡ ³ô°í, °³º°È­µÈ ÀǾàǰ¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
    • ÀÚµ¿È­ ½Ã½ºÅÛÀÇ ¼öµ¿ 󸮿¡ ´ëÇÑ ¿î¿µ»óÀÇ ÀÌÁ¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Ä¡·á¹ýÀÇ Â÷ÀÌ¿¡ ÀÇÇÑ »ý¹°ÇÐÀû º¯ÀÌ
  • ½ÃÀå ±âȸ
    • ÀÚµ¿ ¼¼Æ÷ Ä¡·á ó¸® ½Ã½ºÅÛÀÇ ¿¬±¸ °³¹ßÀÇ ÁøÀü
    • °í±Þ Ä¡·á °³¹ß ÀýÂ÷¿Í ¼ÒÇÁÆ®¿þ¾î ±â¼úÀÇ ÅëÇÕ
  • ½ÃÀåÀÇ °úÁ¦
    • ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·°ú ÀÚµ¿È­ÀÇ º¹ÀâÇÑ ÇÁ·Î¼¼½º

Porter's Five Forces : ÀÚµ¿ ¹× Æó¼â Çü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÔÀ¸·Î½á º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå¿¡¼­ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀÚµ¿ ¹× Æó¼â Çü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. Á¤Ä¡, °æÁ¦, »çȸ, ±â¼ú, ¹ý ¹× ȯ°æ ¿äÀÎ ºÐ¼® ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸ Á¦°øÇÕ´Ï´Ù.PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ¾ÕÀ» ³»´Ùº¸°í Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡µÇ¾î ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´×, ¸ÅÆ®¸¯½º ÀÚµ¿ ¹× Æó¼â Çü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀå¿¡¼­ º¥´õ¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷ Ä¡·á ½Ã½ºÅÛ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ ÇÁ·¹Á𽺠°­È­¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÌ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Àç»ý ÀÇ·á¿Í ¼¼Æ÷ ¿ä¹ýÀÇ ÀαⰡ ³ô¾Æ
      • ºñ¿ë È¿À²ÀûÀÎ °³ÀÎÈ­ ÀǾàǰ¿¡ ´ëÇÑ ¿ä±¸ Áõ°¡
      • ¼öµ¿ 󸮿¡ ´ëÇÑ ÀÚµ¿È­ ½Ã½ºÅÛÀÇ ¿î¿µ»óÀÇ ÀÌÁ¡
    • ¾ïÁ¦¿äÀÎ
      • ´Ù¸¥ Ä¡·á¹ý°ú °ü·ÃµÈ »ý¹°ÇÐÀû º¯ÀÌ
    • ±âȸ
      • ÀÚµ¿ ¼¼Æ÷ Ä¡·á ó¸® ½Ã½ºÅÛÀÇ ¿¬±¸ °³¹ß Ȱµ¿ ÃßÁø
      • ÷´Ü Ä¡·á °³¹ß ÀýÂ÷¿Í ¼ÒÇÁÆ®¿þ¾î ±â¼úÀÇ ÅëÇÕ
    • °úÁ¦
      • ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·°ú ÀÚµ¿È­ÀÇ º¹ÀâÇÑ ÇÁ·Î¼¼½º
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå : ¿öÅ©Ç÷ο캰

  • ¾ÆÆä·¹½Ã½º
  • µ¿°áº¸Á¸
  • È®´ë
  • ÃæÀü-¸¶¹«¸®
  • ºÐ¸®

Á¦7Àå ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå : À¯Çüº°

  • ºñÁٱ⼼Æ÷¿ä¹ý
  • Áٱ⼼Æ÷¿ä¹ý

Á¦8Àå ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå ½ºÄÉÀϺ°

  • »ó¾÷±Ô¸ð
  • ÇÁ¸®Ä¿¸Ó¼È ¶Ç´Â R&D ½ºÄÉÀÏ

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÚµ¿ ¹× Æó¼âÇü ¼¼Æ÷Ä¡·á ½Ã½ºÅÛ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Bio-Techne Corporation
  • BioLife Solutions Inc.
  • BioSpherix, Ltd.
  • Cellares Inc.
  • Corning Incorporated
  • Cytiva
  • Danaher Corporation
  • Fresenius SE & Co. KGaA
  • General Electric Company
  • Lonza Group AG
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • Novartis AG
  • Pluristem Therapeutics Inc.
  • Regeneus Ltd.
  • Sartorius AG
  • STEMCELL Technologies Canada Inc.
  • Terumo Corporation
  • Thermo Fisher Scientific, Inc.
  • Thermogenesis Holdings, Inc.
BJH 24.12.16

The Automated & Closed Cell Therapy Processing Systems Market was valued at USD 943.94 million in 2023, expected to reach USD 1,087.97 million in 2024, and is projected to grow at a CAGR of 15.74%, to USD 2,626.76 million by 2030.

Automated & Closed Cell Therapy Processing Systems are essential components of modern regenerative medicine, focusing on the manufacture and scaling of therapies such as stem cell treatments and gene therapies. These systems enable reproducible, safe, and sterile production processes, ensuring consistency and regulatory compliance in cell therapy products. Their necessity stems from the burgeoning demand for effective cell-based treatments for complex diseases, requiring scalable, efficient, and cost-effective production solutions. Applications span the pharmaceutical and biotechnology sectors, academic research, and clinical laboratories. These systems are pivotal in producing CAR-T cells, stem cells, and other cellular products used in regenerative medicine, offering end-use benefits in treating cancers, genetic disorders, and degenerative diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 943.94 million
Estimated Year [2024] USD 1,087.97 million
Forecast Year [2030] USD 2,626.76 million
CAGR (%) 15.74%

Market growth is primarily driven by advancements in cell therapy technologies, increasing research funding, and heightened awareness and adoption of regenerative medicine. The key growth factors include technological innovations in bioprocessing, increasing clinical trial activities, and strategic collaborations between biotech firms and research institutions. Opportunities lie in optimizing these systems for cost-efficiency and developing integrated platforms offering real-time monitoring and AI-driven quality control. Companies should focus on enhancing automation technologies, simplifying user interfaces, and ensuring regulatory compliance to capitalize on emerging market possibilities.

Challenges such as the high cost of system implementation, stringent regulatory landscapes, and technical complexities can impede growth. Moreover, skilled personnel shortages and the need for continuous updates in response to evolving therapeutic technologies also pose hurdles. To overcome these challenges, businesses should invest in training programs and collaborate with academic institutions for innovation. Areas ripe for innovation and research include advancing modular system designs, exploring new cell types for therapy, and integrating IoT for enhanced process control. The market is dynamic, characterized by rapid advancements and competitive pressures, necessitating continuous innovation and strategic positioning to leverage the burgeoning demand for cell therapies globally efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Automated & Closed Cell Therapy Processing Systems Market

The Automated & Closed Cell Therapy Processing Systems Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising popularity of regenerative medicines & cell therapies
    • Growing need for cost-effective and personalized drugs
    • Operational superiority of automated systems over manual processing
  • Market Restraints
    • Biological variations associated with different therapies
  • Market Opportunities
    • Advancing research and development activities in automated cell therapy processing systems
    • Integration of advanced therapy development procedures and software technologies
  • Market Challenges
    • Lack of skilled professionals and complicated process of automation

Porter's Five Forces: A Strategic Tool for Navigating the Automated & Closed Cell Therapy Processing Systems Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Automated & Closed Cell Therapy Processing Systems Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Automated & Closed Cell Therapy Processing Systems Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Automated & Closed Cell Therapy Processing Systems Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Automated & Closed Cell Therapy Processing Systems Market

A detailed market share analysis in the Automated & Closed Cell Therapy Processing Systems Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Automated & Closed Cell Therapy Processing Systems Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Automated & Closed Cell Therapy Processing Systems Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Automated & Closed Cell Therapy Processing Systems Market

A strategic analysis of the Automated & Closed Cell Therapy Processing Systems Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Automated & Closed Cell Therapy Processing Systems Market, highlighting leading vendors and their innovative profiles. These include Bio-Techne Corporation, BioLife Solutions Inc., BioSpherix, Ltd., Cellares Inc., Corning Incorporated, Cytiva, Danaher Corporation, Fresenius SE & Co. KGaA, General Electric Company, Lonza Group AG, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Novartis AG, Pluristem Therapeutics Inc., Regeneus Ltd., Sartorius AG, STEMCELL Technologies Canada Inc., Terumo Corporation, Thermo Fisher Scientific, Inc., and Thermogenesis Holdings, Inc..

Market Segmentation & Coverage

This research report categorizes the Automated & Closed Cell Therapy Processing Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Workflow, market is studied across Apheresis, Cryopreservation, Expansion, Fill- Finish, and Separation.
  • Based on Type, market is studied across Non-Stem Cell Therapy and Stem Cell Therapy.
  • Based on Scale, market is studied across Commercial Scale and Pre-commercial or R&D Scale.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising popularity of regenerative medicines & cell therapies
      • 5.1.1.2. Growing need for cost-effective and personalized drugs
      • 5.1.1.3. Operational superiority of automated systems over manual processing
    • 5.1.2. Restraints
      • 5.1.2.1. Biological variations associated with different therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancing research and development activities in automated cell therapy processing systems
      • 5.1.3.2. Integration of advanced therapy development procedures and software technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of skilled professionals and complicated process of automation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Automated & Closed Cell Therapy Processing Systems Market, by Workflow

  • 6.1. Introduction
  • 6.2. Apheresis
  • 6.3. Cryopreservation
  • 6.4. Expansion
  • 6.5. Fill- Finish
  • 6.6. Separation

7. Automated & Closed Cell Therapy Processing Systems Market, by Type

  • 7.1. Introduction
  • 7.2. Non-Stem Cell Therapy
  • 7.3. Stem Cell Therapy

8. Automated & Closed Cell Therapy Processing Systems Market, by Scale

  • 8.1. Introduction
  • 8.2. Commercial Scale
  • 8.3. Pre-commercial or R&D Scale

9. Americas Automated & Closed Cell Therapy Processing Systems Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Automated & Closed Cell Therapy Processing Systems Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Automated & Closed Cell Therapy Processing Systems Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Bio-Techne Corporation
  • 2. BioLife Solutions Inc.
  • 3. BioSpherix, Ltd.
  • 4. Cellares Inc.
  • 5. Corning Incorporated
  • 6. Cytiva
  • 7. Danaher Corporation
  • 8. Fresenius SE & Co. KGaA
  • 9. General Electric Company
  • 10. Lonza Group AG
  • 11. Merck KGaA
  • 12. Miltenyi Biotec B.V. & Co. KG
  • 13. Novartis AG
  • 14. Pluristem Therapeutics Inc.
  • 15. Regeneus Ltd.
  • 16. Sartorius AG
  • 17. STEMCELL Technologies Canada Inc.
  • 18. Terumo Corporation
  • 19. Thermo Fisher Scientific, Inc.
  • 20. Thermogenesis Holdings, Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦